TEST:

DecisionDx®-Melanoma

#TeamCastle is headed to the Crescent City for #AAD2023! Visit us at booth 4051 Friday - Sunday. #SeeYouThere #CastleCares @AADmember #GeneExpressionProfile #GEP #DecisionDxMelanoma #DecisionDxSCC #MyPathMelanoma ()

Here's where you can find #TeamCastle in February. Hope to see you there! #CastleOnTheRoad #DecisionDxMelanoma #DecisionDxSCC #MyPathMelanoma #DiffDxMelanoma ()

NCCN Melanoma 2023 updates: Basically no change regarding prognostic gene expression profile (GEP) tests. DecisionDx Melanoma, Merlin test, etc still not recommended. $CSTL @skylinedx ()

Scenes from day 5 of the Winter Clinical Dermatology Conference Hawaii #WCH23. Stop by and visit us! @fallclinical #DecisionDxMelanoma #DecisionDxSCC #MyPathMelanoma #DiffDxMelanoma ()

$CSTL Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma https://t.co/H7Mp2uCQu4 (@stock_titan)

$CSTL Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk https://t.co/97uOmpESOM (@stock_titan)

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma https://t.co/vvyDKQSUxm (@NewsFromBW)

"Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma https://t.co/NtxCPBdoWM" (@NewsFromBW)